share_log

Coeptis Therapeutics Adds Autoimmune Indications To Exclusive License Agreement With University Of Pittsburgh For SNAP-CAR T And SNAP-CAR NK

Coeptis Therapeutics Adds Autoimmune Indications To Exclusive License Agreement With University Of Pittsburgh For SNAP-CAR T And SNAP-CAR NK

Coeptis Therapeutics在與匹茲堡大學簽訂的SNAP-CAR T和SNAP-CAR NK的獨家許可協議中增加了自身免疫適應症
Benzinga ·  02/26 22:02

Exclusive rights to universal CAR technology platform designed to target multiple antigens simultaneously, recently expanded to include SNAP-CAR NK cells, has potential to impact various autoimmune diseases in addition to oncology indications.

通用CAR技術平台的專有權利旨在同時靶向多種抗原，該平台最近擴大到包括SNAP-CAR NK細胞，除了腫瘤學適應症外，還可能影響各種自身免疫性疾病。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論